Cullinan Therapeutics, Inc. (CGEM) - Q2 2026 10-Q Summary
Business Context and Reporting Period
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disease-modifying T cell engagers for autoimmune diseases and cancer. This report covers the quarterly period ended June 30, 2026. The company is currently a smaller reporting company but expects to lose this status after December 31, 2026, becoming a large accelerated filer in 2027 due to its public float exceeding $700 million.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(53.7) million | $(70.1) million | $(103.4) million | $(118.6) million |
| Operating Expenses | $57.3 million | $75.8 million | $111.0 million | $130.8 million |
| Research & Development (R&D) | $44.4 million | $61.0 million | $86.6 million | $102.5 million |
| General & Administrative (G&A) | $12.8 million | $14.8 million | $24.4 million | $28.3 million |
| Interest Income | $3.6 million | $5.9 million | $7.7 million | $12.5 million |
| Cash & Investments (Total) | $355.9 million (as of June 30, 2026) | |||
| Cash Burn (Operating) | $84.3 million (YTD 2026) |
Note: All figures in millions unless otherwise noted. The company has no product revenue and operates at a loss.
Material Changes vs. Prior Period
- Reduced Operating Loss: Net loss decreased by approximately 23% in Q2 2026 compared to Q2 2025, driven primarily by a $20.0 million one-time upfront license fee paid in June 2025 for the velinotamig asset, which did not recur in 2026.
- R&D Expense Shifts: While total R&D expenses decreased, spending on specific programs increased. CLN-978 (autoimmune) and Velinotamig (autoimmune) saw significant expense increases due to clinical trial progression, offsetting the absence of the 2025 license fee.
- Discontinued Programs: The company discontinued development of CLN-619 (gynecological cancers and NSCLC) and CLN-617 (solid tumors) in late 2025, resulting in minimal associated costs in Q2 2026.
- Investment Portfolio: Total investments decreased from $347.8 million at year-end 2025 to $274.9 million at June 30, 2026, reflecting maturities and purchases of marketable securities.
Outlook, Guidance, and Risks
- Liquidity: Management expects current cash, cash equivalents, and investments ($355.9 million) to fund operations for at least the next 12 months. No sales were made under the At-The-Market (ATM) equity program in Q2 2026.
- Key Milestones:
- Zipalertinib: FDA NDA accepted for review (Feb 2027 action date) for NSCLC. Phase 3 trial (REZILIENT3) enrollment completed; top-line results expected end of 2026.
- CLN-049: Registrational Phase 2 trial for AML to begin Q3 2026 following positive FDA End-of-Phase 1 meeting.
- CLN-978: Phase 2 expansion in SLE and RA expected to begin early 2027.
- Risks:
- Regulatory Approval: Success depends on FDA approval of product candidates, particularly zipalertinib.
- Capital Requirements: Continued operating losses require future financing; dilution is possible if equity is raised.
- Compliance Status Change: Transition to "large accelerated filer" status in 2027 will increase compliance costs and reporting requirements (e.g., SOX 404(b) attestation).
Investor Verification Checklist
- Verify the timeline and potential outcomes of the zipalertinib NDA review (target action date Feb 27, 2027) and the REZILIENT3 Phase 3 results expected late 2026.
- Monitor cash burn rates against the $355.9 million liquidity position to assess runway sufficiency beyond the 12-month projection.
- Review the progress of the CLN-049 Phase 2 trial initiation in Q3 2026 and the CLN-978 Phase 2 expansion planned for early 2027.
- Assess the impact of the upcoming loss of "smaller reporting company" status on future operating expenses and compliance costs.
- Confirm the status of the ATM equity facility and whether the company will utilize it to fund future operations.